News | November 10, 2021
Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastrointestinal ulcer when a rapid effect is desired or when oral medication is not tolerated
The company has operations in North America, Asia, and Europe,
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Subscribe To Our Newsletter & Stay Updated
